INTERLEUKIN-18 GENE POLYMORPHISM IN EGYPTIAN ASTHMATIC CHILDREN

Thesis submitted for partial fulfillment of master degree in Pediatrics

Presented by

Amira Ahmed Abd El Wahab

M.B.B.Ch.

Supervised by

Dr. Hala Hamdi Shaaban

Professor of Pediatrics
Faculty of Medicine- Cairo University

Dr. Abeer Mohamed Mohy

Assistant Professor of Clinical and Chemical Pathology
Faculty of Medicine- Cairo University

Dr. Abdel-Rahman Ahmed Abdel-Razek

Lecturer of Pediatrics

Faculty of Medicine- Cairo University

Faculty of Medicine
Cairo University
2012

ABSTRACT

Asthma is a multifactorial respiratory disease determined by interactions of multiple disease susceptibility genes and environmental factors. IL-18 is an important cytokine for initiating and perpetuating the catabolic and inflammatory response in allegic asthma. A number of SNPs that influence IL-18 production are found in the gene promoter region.

The aim of this study was to investigate the association of IL-18 -607 C/A promoter polymorphism with asthma and whether this polymorphism influenced the severity of asthma in affected children. The influence of this promoter gene polymorphism on total serum IgE level in studied subjects was investigated.

This study included 40 asthmatic children, subdivided into four groups according to different degrees of asthma severity, and 20 healthy subjects were included as control group.

Key Words:

Definition of Asthma, Incidence and Prevalence of Asthma, Etiology of Asthma, Pathogenesis of Asthma, Gene Polymorphism in Asthma, Diagnosis of Asthma, Asthma Classification, Asthma Management and Prevention, Cytokines and Bronchial Asthma, Interleukin-18.

Acknowledgements

First of all, I would like to thank GOD, who gave me the power by his abundant grace to produce this piece of work

I would like to express my appreciation and sincere gratitude to **Prof. Dr. Hala Hamdi Shaaban**, Professor of Pediatrics, Faculty of Medicine, Cairo University, who enriched the study with her experience and knowledge, and provided me with her valuable instructions, sincere help and support.

I am very grateful to **Dr. Abeer Mohamed Mohy**, Assistant Professor of Clincal and Chemical Pathololgy, Faculty of Medicine, Cairo University, not only for her kind assistance, support, but also for her patience with constant guidance and effort.

Sincere thanks to **Dr. Abdel Rahman Ahmed Abdel Razek**, Lecturer of Pediatrics, Faculty of
Medicine, Cairo University, for his help and
encouragement throughout this work.

I will always be grateful to my parents, my sister, and my husband for all their love, support and understanding.

To all patients, for whose benefit the present study was conducted, I wish it would help you a step forward.

List of contents

Content	Page
List of abbreviations	I
List of tables	III
List of figures	IV
Introduction and aim of work	1
Review of literature	
Definition of asthma	4
 Incidence and prevalence of asthma 	5
Etiology of asthma	6
Pathogenesis of asthma	14
Gene polymorphism in asthma	21
Diagnosis of asthma	23
Asthma classification	36
Asthma management and prevention	40
Cytokines and bronchial asthma	58
Interleukin-18	64
Subjects and methods	67
Results	88
Discussion	107
Summary and conclusion	117
Recommendations	119
References	120
Arabic summary	-

List of abbreviations

AEC	Absolute eosinophilic count
AHR	Airway hyper-responsiveness
AMP	Adenosine 5'-monophosphate
APCS	antigen presenting cells
ASCIA	Australasian Society of Clinical Immunology and Allergy
ASM	Airway smooth muscle
BAL	Broncho-alveolar lavage
CBC	Complete blood count
CCL	CC chemokine
CCR	CC chemokine receptor
CD	Cluster of differentiation antigen
COPD	Chronic obstructive pulmonary disease
CVA	Cough variant asthma
CXCL	CXC chemokine
CXCR	CXC chemokine receptor
DNA	Deoxyribonucleic Acid
EDTA	Ethylenediaminetetra-acetic acid
EGF	Epidermal growth factor
EIA	Exercise-induced asthma
ELISA	Enzyme-linked immunosorbant assay
FEF	Forced expiratory flow
FEV1	Forced expiratory volume in one second
FeNO	Fractional exhaled nitrous oxide
FVC	Forced vital capacity

GERD	Gastroesophageal reflux disease
GINA	Global initiative for asthma program
GM-CSF	Granulocyte macrophage –colony stimulating factor
GWAS	Genome-wide association studies
НВ	Hemoglobin
HRCT	High resolution computed tomography
ICS	Inhaled corticosteroids
IgE	Immunoglobulin E
IL	Interleukin
INF-γ	Interferon-gamma
LABA	Long-acting beta2-agonist
LTE4	Leukotriene E4
LTRAs	Leukotrienes receptor antagonists
MBP	Major basic protein
MDC	Monocyte-derived chemokines
NAEPP	National Asthma Education and Prevention Program
NHLBI	National Heart, Lung and Blood Institute
NGF	Nerve growth factor
NO	Nitric oxide
PAF	Platelet-activating factor
PCR	Polymerase chain reaction
PEF	Peak expiratory flow
PEFR	Peak expiratory flow rate
PLT	Platelet
RADS	Reactive airways dysfunction syndrome
RAST	RadioAllergoSorbent Test

RFLP	Restriction fragment length polymorphism
RSV	Respiratory syncytial virus
SABA	Short-acting beta2-agonist
SCF	Stem cell factor
SFC	Salmeterol/fluticasone propionate combination
SNP	Single-nucleotide polymorphism
SPT	Skin prick testing
SVT	Supraventricular tachycardia
TARC	Thymus and activation-regulated chemokine
TGF-β	Transforming growth factor beta
Th1	T-helper 1
Th2	T- helper 2
TLC	Total leucocytic count
TMG	Tetramethylguanidine
TNF	Tumor necrosis factor
TSLP	Thymic stromal lymphopoietin
VEGF	Vascular endothelial growth factor
WHO	World health organization

List of Tables

Table no	Title	Page
1	Factors influencing the development and expression of asthma.	7
2	Questions to consider in the diagnosis of asthma.	24
3	Differential diagnosis of asthma.	35
4	Classification of asthma severity.	38
5	Levels of Asthma Control.	39
6	Estimated Equipotent daily doses of inhaled glucocorticosteroids	48
	for children older than 5 years.	
7	Key cytokines involved in asthma.	60
8	Normal ranges for total IgE (IU/mL) in relation to age group	73
9	Age and sex distribution among studied groups	88
10	Frequency (number) and percentage (%) of asthmatic patients	90
	(males and females) according to their clinical data	
11	Comparative study of laboratory parameters among studied	94
	groups (cases and controls.	
12	Comparison of frequencies of IL-18-607 C/A genotypes among	96
	studied groups.	
13	Frequency and risk estimate of (AA & CA) genotypes between	97
	cases and control group.	
14	IL-18-607 C/A genotype frequency among asthmatic patients	98
	according to different degrees of clinical severity	
15	Frequency and risk estimate of (AA & CA) genotypes between	99
	asthmatics with mild persistent severity and those with	

intermittent severity.	
Frequency and risk estimate of (AA & CA) genotypes between	99
asthmatics with intermittent severity and those with moderate	
and severe persistent type.	
IL-18-607 C/A genotype frequency and risk estimate in	100
asthmatic patients with atopic manifestations.	
IL-18 607 C/A genotype frequency and risk ratio in asthmatic	100
patients with family history of atopy.	
Allele frequency and risk estimate of IL-18-607 C/A in the	101
studied groups.	
Frequency of IL-18-607 (A) allele among asthmatic patients	102
according to different degrees of clinical severity.	
Frequency and risk estimate of (A) allele between asthmatics	103
with mild persistent severity and those with intermittent severity.	
Frequency and risk estimate of (A) allele between asthmatics	104
with intermittent severity and those with moderate and severe	
persistent type.	
Median total serum IgE levels among IL-18-607 C/A genotypes	105
in studied subjects.	
Median absolute eosinophilic count among IL-18-607 C/A	106
genotypes in studied	
subjects.	
	Frequency and risk estimate of (AA & CA) genotypes between asthmatics with intermittent severity and those with moderate and severe persistent type. IL-18-607 C/A genotype frequency and risk estimate in asthmatic patients with atopic manifestations. IL-18 607 C/A genotype frequency and risk ratio in asthmatic patients with family history of atopy. Allele frequency and risk estimate of IL-18-607 C/A in the studied groups. Frequency of IL-18-607 (A) allele among asthmatic patients according to different degrees of clinical severity. Frequency and risk estimate of (A) allele between asthmatics with mild persistent severity and those with intermittent severity. Frequency and risk estimate of (A) allele between asthmatics with intermittent severity and those with moderate and severe persistent type. Median total serum IgE levels among IL-18-607 C/A genotypes in studied subjects. Median absolute eosinophilic count among IL-18-607 C/A genotypes in studied

List of figures

Figure	Title	Page
no		
1	Differentiation of CD4 Th cells into Th1 and Th2	17
2	Spirogram	30
3	Management approach based on control for children older than 5	45
	years, adolescents and adults	
4	Management approach based on control for children younger	46
	than 5 years	
5	Management of asthma exacerbations in acute care setting	55
6	PCR-based RFLP analysis of IL-18 -607 C/A polymorphism	86
7	Comparing the median values of age between asthmatic patients	89
	and control group	
8	Sex distribution among cases.	89
9	Sex distribution among control group	89
10	Comparison between male and females asthmatic patients as	92
	regarding degree of asthma severity.	
11	Comparison between male and females asthmatic patients as	92
	regarding Precipitating factors for asthma.	
12	Comparison between male and females asthmatic patients as	93
	regarding atopic manifestations and family history of atopy	
13	Comparison between male and female asthmatic patients as	93
	regarding types of medications received	
14	Median levels of total serum IgE between cases and control	95

15	Median levels of absolute eosinophilic count between cases and	95
	control groups	
16	Distribution of IL-18-607 C/A genotypes among studied groups	96
17	Frequency and risk estimate of (AA & CA) genotypes between	97
	cases and control group	
18	IL-18 607 C/A genotype frequency among asthmatic patients with	98
	different degrees of clinical severity	
19	Allele frequency between cases and control	101
20	Frequency of IL-18-607 (A) allele among asthmatic patients with	102
	different degrees of clinical severity	
21	Frequency and risk ratio of A allele between asthmatics with mild	103
	persistent severity and those with intermittent severity	
22	Frequency and risk ratio of (A) allele between asthmatics with	104
	intermittent severity and those with moderate and severe	
	persistent type	
23	Median total serum IgE levels among IL-18-607 C/A genotypes in	105
	studied subjects.	

INTRODUCTION

Asthma is a syndrome characterized by intermittent narrowing of the small airways of the lung, with subsequent airflow obstruction and symptoms of wheeze, cough and breathlessness. An important characteristic of asthma is airways hyper-responsiveness, which is the exaggerated narrowing of the airways in response to provocative agents (Settin et al., 2008).

As a chronic inflammatory disease, many of the researches related to asthma has been focused on pro-inflammatory mechanisms, advances have been made in defining mechanisms that control inflammation and induce immune tolerance to specific antigens (Gern and Seroogy, 2005).

Recently, new insights in the pathogenesis of asthma suggest the role of lymphocytes; airway inflammation in asthma may represent a loss of normal balance between two "opposing "populations of T-helper (Th) lymphocytes. Two types of Th lymphocytes have been characterized: Th1 and Th2. Th1 cells produce interleukin (IL)-2 and interferon (IFN)-gamma which are critical in cellular defense mechanisms and promote proinflammatory immune reaction in response to infection. Th2, in contrast, generates a family of cytokines (IL-4, IL-5, IL-6, IL-9, and IL-13) that can mediate allergic inflammation and promote antibody dependent immune response. As a result, there is a great interest in using cytokines as markers of human immune function (Sharma, 2010).

Inerleukin-18(IL-18) is unique cytokine that enhances innate immunity and both Th-1and Th-2 driven immune responses (**Abdel Naser et al., 2009**), it was originally described as interferon-gamma releasing factor, but has a different mechanism of action to IL-12 (**Barnes, 2001**), where it was recently found to act in synergy with IL-12 to promote the development of Th2 immune response by induction of IL-13. So, according to its role in regulation of Th1/Th2 balance, IL-18 is considered as a candidate asthma susceptibility gene (**Lachheb et al., 2007**).

For the past few years, studies were made to determine the gene loci predisposing to asthma and other atopic disorders & by the completion of the human Genome Project, analysis of single-nucleotide polymorphisms (SNP) has become the newest approach in the detection and localization of the genetic determinants of the human disease (**Li et al., 2009**).

Based on these studies, it was found that cytokine gene polymorphism could affect the serum levels of cytokines by influencing transcriptional regulation (Amirzargar et al., 2009).

AIM OF WORK

The aim of the present study is to investigate whether the presence of IL-18-607 C/A polymorphism was associated with asthma (or atopy) and whether this polymorphism influenced the severity of asthma in affected children. We examine also the relationship between the IL-18 gene polymorphism and the serum total IgE level.

DEFINITION OF ASTHMA

Asthma is a chronic inflammatory disorder of the airways characterized by an obstruction of airflow, which may be completely or partially reversed with or without specific therapy. In susceptible individuals, airway inflammation may cause recurrent or persistent bronchospasm, which causes symptoms including wheezing, breathlessness, chest tightness, and cough, particularly at night or after exercise (Sharma, 2010). Airway inflammation is associated with airway hyper reactivity or bronchial hyper responsiveness (BHR), which is defined as the inherent tendency of the airways to narrow in response to various stimuli (eg, environmental allergens and irritants) (NHLBI, 2007).

Although the cause of childhood asthma has not been determined, contemporary research implicates a combination of environmental exposures and inherent biological and genetic vulnerabilities (Liu et al., 2007)